Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1641 1644
This examiner grants 64% of resolved cases
Hilary Ann Petrash is an examiner in Tech Center 1600 and Art Unit 1641. There are 62 resolved cases associated with this profile. These 62 cases provide the data for the allowance and pendency metrics.
The allowance rate is 64.5%. This 64.5% rate indicates the frequency of allowances among the resolved cases. The median days to allowance is 1155. This 1155-day figure is the median time taken to reach a grant.
The interview lift is 51.7%. This 51.7% lift shows the increase in allowance probability when an interview is held. For practitioners in Art Unit 1641, the 1155-day median pendency is a factor in planning. The 64.5% allowance rate and the 51.7% interview lift are relevant for determining whether to request an interview. Direct communication with the examiner in Tech Center 1600 is a tactical option. The 62 resolved cases establish the statistical context for these prosecution trends.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18509777 | Compositions And Methods Of MAIT Cell Activation | Non-Final OA | ImmunityBio, Inc. |
| 17539926 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR DEMENTIA | Final Rejection | TEIJIN PHARMA LIMITED |
| 18753316 | ANTIBODY MOLECULES AND CONJUGATES | Non-Final OA | ASTRAZENECA AB |
| 17637305 | INTERCELLULAR ADHESION MOLECULE 1 (ICAM1) ANTIBODY DRUG CONJUGATE AND USES THEREOF | Final Rejection | Children's Medical Center Corporation |
| 17491813 | EVALUATION AND TREATMENT OF BRADYKININ-MEDIATED DISORDERS | Final Rejection | Takeda Pharmaceutical Company Limited |
| 18910550 | ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF | Non-Final OA | KEYMED BIOSCIENCES CO., LTD |
| 18036289 | COMBINATION OF ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPalpha ANTIBODY | Non-Final OA | DAIICHI SANKYO COMPANY, LIMITED |
| 18682886 | METHODS FOR TREATING NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | Non-Final OA | SEAGEN INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy